Core Viewpoint - Shares of Aquestive Therapeutics, Inc. (NASDAQ: AQST) dropped approximately 40% intraday following the FDA's identification of deficiencies in its New Drug Application (NDA) for Anaphylm, an experimental treatment for severe allergic reactions, including anaphylaxis [1] Group 1 - The FDA's findings prevent discussions regarding labeling and post-marketing requirements, raising concerns about the approvability of the application ahead of the January 31, 2026, PDUFA action date [1]

Core Viewpoint - The content emphasizes the importance of conducting personal due diligence and consulting with competent advisors before making any financial decisions, particularly in relation to investments in cryptocurrencies and CFDs [1]. Group 1 - The website provides general news, personal analysis, and opinions, as well as materials from third parties for educational and research purposes [1]. - It explicitly states that the information should not be interpreted as a recommendation or advice for any financial actions, including investments or purchases [1]. - The content is not tailored to individual financial situations or needs, highlighting the necessity for users to exercise their own discretion [1]. Group 2 - The website includes information about complex financial instruments such as cryptocurrencies and CFDs, which carry a high risk of losing money [1]. - Users are encouraged to conduct their own research and fully understand the workings and risks of any financial instruments before investing [1]. - The website may feature advertisements and promotional content, and FX Empire may receive compensation from third parties related to such content [1].

Core Viewpoint - Rosen Law Firm is reminding former stockholders of Smartsheet Inc. about a class action lawsuit related to the January 2025 sale of Smartsheet to a consortium including Blackstone, Vista Equity Partners, and Platinum Falcon, with a lead plaintiff deadline of February 24, 2026 [1]. Group 1: Class Action Details - Former Smartsheet stockholders may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [3][6]. - The complaint alleges that Smartsheet's solicitation of stockholder approval for the Buyout involved a misleading Proxy statement that mischaracterized the company's financial performance [5]. Group 2: Legal Representation - Investors are encouraged to select qualified legal counsel with a proven track record in securities class actions, as many firms may not have the necessary experience [4]. - Rosen Law Firm has a history of successful settlements in securities class actions, including significant recoveries for investors [4].

Core Insights - Beta Bionics experienced a significant decline in stock price following the release of preliminary fourth-quarter 2025 performance metrics that did not meet market expectations [1] - The company reported lower-than-expected new patient starts for its iLet automated insulin delivery system, raising concerns among investors about short-term adoption trends and revenue growth [1] - On January 9, 2026, Beta Bionics' stock fell approximately $11.85, or 37.04%, closing at $20.14 [1]

Brief Overview:Frasers Centrepoint Trust (SGX: J69U), or FCT, is Singapore’s largest suburban retail mall REIT. As at 30 September 2025, its portfolio comprises of the following retail malls: Causeway Point, Century Square, Hougang Mall, NEX (50% interest), Northpoint City, Tampines 1, Tiong Bahru Plaza, Waterway Point (50% interest), and White Sands. This is in addition to an office property in Central Plaza in Tiong Bahru. Collectively, its properties are worth approximately S$8.3 billion. Portfolio Occup ...

Core Viewpoint - The prices of precious metals have surpassed the significant threshold of $5,000 per ounce for the first time, indicating a notable shift in market dynamics [1] Group 1 - Precious metal prices have reached a new high, climbing above $5,000 per ounce [1]

Core Viewpoint - Wealthfront Corporation's shares have experienced a significant decline following its first earnings report post-IPO, primarily due to disappointing asset flow figures and investor concerns regarding its mortgage business strategy [1]. Group 1: Stock Performance - Since its IPO on December 12, 2025, at a price of $14.00 per share, Wealthfront's stock has decreased by $3.74, representing a 26.71% drop, closing at $10.26 on January 14, 2026 [2]. Group 2: Financial Metrics - The company reported softer net inflows in recent months, indicating a slowdown in client acquisitions and cash management balances compared to previous periods [1]. Group 3: Investor Concerns - Increased scrutiny over the CEO's ownership stake in a banking partner, which is crucial to Wealthfront's mortgage initiative, has raised investor concerns about potential conflicts of interest and long-term integration risks [1].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Coupang, Inc. securities between August 6, 2025, and December 16, 2025, about the upcoming lead plaintiff deadline for a class action lawsuit set for February 17, 2026 [1]. Group 1: Class Action Details - Investors who bought Coupang securities during the specified Class Period may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by February 17, 2026 [3]. - Investors can join the class action by visiting the provided link or contacting the law firm directly for more information [6]. Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting their own achievements in this area [4]. - The firm has secured significant settlements for investors, including over $438 million in 2019 alone, and has been recognized as a leader in the field of securities class action litigation [4]. Group 3: Case Allegations - The lawsuit alleges that Coupang made false and misleading statements regarding its cybersecurity protocols, which allowed unauthorized access to sensitive customer information for nearly six months [5]. - It is claimed that the company failed to disclose this data breach, leading to increased regulatory and legal scrutiny, and that public statements made by the defendants were materially false and misleading [5].

Core Insights - The complaint alleges that BellRing and its executives violated federal securities laws by making false or misleading statements regarding the sustainability and drivers of sales growth, as well as the impact of competition on product demand [2] Group 1: Sales Performance and Market Reaction - On May 5, 2025, BellRing disclosed that several key retailers reduced their weeks of supply, which would negatively impact Q3 2025 growth. The stock price fell by $14.88, or 19%, from $78.43 to $63.55 on May 6, 2025, with unusually high trading volume [3] - On August 4, 2025, BellRing reported disappointing quarterly consumption of Premier Protein RTD Shakes, which aligned more closely with shipments than expected. This led to a stock price drop of $17.46, or nearly 33%, from $53.64 to $36.18 on August 5, 2025 [4] Group 2: Legal Proceedings - The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class, who will oversee the litigation on behalf of the class members. Class members can choose to serve as lead plaintiff or remain absent without affecting their ability to share in any recovery [5] - Faruqi & Faruqi encourages individuals with information regarding BellRing's conduct to come forward, including whistleblowers and former employees [6]

U.S. President Donald Trump speaks to reporters over the North Atlantic as he returns to Washington from the World Economic Forum (WEF) in Davos, Switzerland, aboard Air Force One, U.S., January 22, 2026."Good fences make good neighbors," goes the saying — one that seems to encapsulate U.S. President Donald Trump's threat of slapping tariffs of 100% on Canada if the country strikes a trade deal with China.  That comes after Trump on Thursday withdrew his invitation to Canadian Prime Minister Mark Carney for ...